Details

NameSymbolSector
SUVEN LIFE SCIENCES LTD.SUVENHealthcare Research- Analytics & Technology
Open
326.95
High
343.7
Low
326.45
Close
342.35
Volume
598704
Exchange
nse
Time
14-Aug-2026

Outlook

Score:

2.25

Rating:

RISKY

Candlestick Pattern

CandlepatternofSuvenLifeSciencesis
Marubozu
EstimatedStoplossofSuvenLifeSciencesis
326.45
SuvenLifeScienceshasa
Bullishℹ
pattern.
Formationof
Marubozu
candlepatternindicatesSuvenLifeScienceshaschancesof
Continuationℹ
ofthecurrenttrend.

Trend

SuvenLifeSciencesisin
Sideways trendℹ
.
PriceofSuvenLifeSciencesis
Upℹ
by

11.14

%.
Target
Buy@

210.37

Sell@

369.05

Current@

342.35

Volume

ThetradevolumesofSuvenLifeScienceshavebecome
Deficientℹ
ThoughthevolumetrendforSuvenLifeSciencesappears
Bullishℹ
theparticipantsseemtobe
Weak Buyersℹ
ThetradevolumeofSuvenLifeSciencesis

Down

by

70.76

%

Valuation

ThecurrentmarketpriceofSuvenLifeSciencesis
Undervaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth135crandtotalassetsworth135cr,thebalancesheetofSuvenLifeSciencesis:
Balancedℹ
.
Cashflow
SuvenLifeScienceshas
Insufficientℹ
cashflowbecauseitis

₹ 0cr

.Itis
Upℹ
by

100

%.
50% i.e. ₹ 154cr spent in operatingℹ
50% i.e. ₹ 154cr earned in investingℹ
0% in financingℹ
0% in otherℹ
SuvenLifeScienceshas
Poorℹ
cashflowbecausethereis

Shortage

of

₹ 22cr

.Itis
Downℹ
by

170.97

%.
54.76% i.e. ₹ 115cr spent in operatingℹ
44.76% i.e. ₹ 94cr earned in investingℹ
0.48% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
Income
TheincomeofSuvenLifeSciencesis

₹ 4cr

and

Loss

is:

₹ 77cr

SuvenLifeSciencesLossesincreasedby:

50.98

%andIncomeisUpby:

100

%
TheincomeofSuvenLifeSciencesis

₹ 2cr

and

Loss

is:

₹ 51cr

SuvenLifeSciencesLossesincreasedby:

18.6

%andIncomeisUpby:

0

%
TheincomeofSuvenLifeSciencesis

₹ 2cr

and

Loss

is:

₹ 43cr

SuvenLifeSciencesLossesincreasedby:

10.26

%andIncomeisDownby:

33.33

%

Market Cap

Market capital of Suven Life Sciences Ltd. is 3892cr
By using this site you agree to the use of cookies to deliver a better site experience.